SPRO Spero Therapeutics, Inc.

NASDAQ
$1.23

Spero Therapeutics, Inc. (SPRO) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.14 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.4% since its last earnings release on August 12, 2026.

Spero Therapeutics Reported Earnings
Wednesday, August 12, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.14)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.26

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Spero Therapeutics, Inc.

pero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Sector

Healthcare

Charts powered in part by Lightweight Charts™ by TradingView.